# To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

> **NCT05948449** · PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 37 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** S-1, Oxaliplatin, Cadonilimab

## Key facts

- **NCT ID:** NCT05948449
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2025-01
- **Final completion:** 2025-07
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948449, "To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05948449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*